Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Pulmonary Edema D011654 23 associated lipids
Pulmonary Embolism D011655 5 associated lipids
Coronary Disease D003327 70 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Hypersensitivity D006967 22 associated lipids
Hypothyroidism D007037 32 associated lipids
Rhinitis D012220 10 associated lipids
Hypercapnia D006935 5 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Pain, Postoperative D010149 13 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Lee JJ et al. Antithrombotic and antiplatelet activities of Soshiho-tang extract. 2013 BMC Complement Altern Med pmid:23773779
Kim YJ Rhamnetin attenuates melanogenesis by suppressing oxidative stress and pro-inflammatory mediators. 2013 Biol. Pharm. Bull. pmid:23739488
Gremmel T et al. Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy. 2013 J. Atheroscler. Thromb. pmid:23739624
Nakamura A et al. Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. 2013 Circ. J. pmid:23676973
Vazzana N et al. Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. 2013 J Am Heart Assoc pmid:23557750
Dave M and Amin AR Yin-Yang regulation of prostaglandins and nitric oxide by PGD2 in human arthritis: reversal by celecoxib. 2013 Immunol. Lett. pmid:23603366
Bai L et al. [Effects of electro-acupuncture at Zusanli point on gastric and intestinal blood flow in rats with acute necrotizing pancreatitis]. 2013 Sichuan Da Xue Xue Bao Yi Xue Ban pmid:24490517
Aukema HM et al. Dietary fish oil reduces glomerular injury and elevated renal hydroxyeicosatetraenoic acid levels in the JCR:LA-cp rat, a model of the metabolic syndrome. 2013 Br. J. Nutr. pmid:23151363
Kong X et al. High-mobility-group box protein 1A box reduces development of sodium laurate-induced thromboangiitis obliterans in rats. 2013 J. Vasc. Surg. pmid:23069071
Zulyniak MA et al. Fish oil supplementation alters circulating eicosanoid concentrations in young healthy men. 2013 Metab. Clin. Exp. pmid:23522836
Kovarik JJ et al. Eicosanoid modulation by the short-chain fatty acid n-butyrate in human monocytes. 2013 Immunology pmid:23398566
Maenthaisong R et al. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 2013 Apr-Jun Int J Immunopathol Pharmacol pmid:23755755
Dudley A et al. Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin. 2013 Jan-Feb J. Vet. Intern. Med. pmid:23278865
John F et al. Elevated levels of leukotriene B4 and thromboxane B2 distinguish chest pain of cardiac and non cardiac origin. 2013 May-Jun Indian Heart J pmid:23809385
Yu C et al. Effects of danshensu on platelet aggregation and thrombosis: in vivo arteriovenous shunt and venous thrombosis models in rats. 2014 PLoS ONE pmid:25375124
Ross S et al. Association of cyclooxygenase-2 genetic variant with cardiovascular disease. 2014 Eur. Heart J. pmid:24796340
Salazar F et al. Renal effects induced by prolonged mPGES1 inhibition. 2014 Am. J. Physiol. Renal Physiol. pmid:24197070
Kawai VK et al. Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome. 2014 Arthritis Care Res (Hoboken) pmid:24022862
Elsheikh W et al. Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. 2014 Nitric Oxide pmid:24747869
Suarez-Kurtz G Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of oxicam NSAIDs. 2014 Pharmacogenet. Genomics pmid:25003537
Lee HI et al. Response to Suarez-Kurtz's comments on strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. 2014 Pharmacogenet. Genomics pmid:25003538
Shan MQ et al. [Comparative study on effects of Rubiae Radix et Rhizoma and carbonized Rubiae Radix et Rhizoma on acute blood stasis rat model]. 2014 Zhongguo Zhong Yao Za Zhi pmid:24946554
Zhou K et al. A CAPE analogue as novel antiplatelet agent efficiently inhibits collagen-induced platelet aggregation. 2014 Pharmazie pmid:25158573
Maurer K et al. Acetylsalicylic acid enhances tachyphylaxis of repetitive capsaicin responses in TRPV1-GFP expressing HEK293 cells. 2014 Neurosci. Lett. pmid:24495935
Shimizu T et al. Up-regulation of Kv7.1 channels in thromboxane A2-induced colonic cancer cell proliferation. 2014 Pflugers Arch. pmid:23995773
Umar A et al. Effect of Ocimum basilicum L. on cyclo-oxygenase isoforms and prostaglandins involved in thrombosis. 2014 J Ethnopharmacol pmid:24412551
Sahota T et al. Model-based analysis of thromboxane Bâ‚‚ and prostaglandin Eâ‚‚ as biomarkers in the safety evaluation of naproxen. 2014 Toxicol. Appl. Pharmacol. pmid:24667227
Gonçalves LH et al. Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels. 2014 Clin. Chim. Acta pmid:24316050
Jiménez-Romero C et al. Dactyloditerpenol acetate, a new prenylbisabolane-type diterpene from Aplysia dactylomela with significant in vitro anti-neuroinflammatory activity. 2014 Bioorg. Med. Chem. Lett. pmid:24279991
Lee HI et al. Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. 2014 Pharmacogenet. Genomics pmid:24322170
Voisin V et al. Protection of Wistar-Furth rats against postischaemic acute renal injury: role for nitric oxide and thromboxane? 2014 Clin. Exp. Pharmacol. Physiol. pmid:25115485
Zhu Y et al. Effects and mechanisms of Fenofibrate on the secretion of vascular endothelial contraction factors in hypertensive rats. 2014 Genet. Mol. Res. pmid:25078582
Tachi M et al. Mass spectrometric determination of prostanoids in rat hypothalamic paraventricular nucleus microdialysates. 2014 Auton Neurosci pmid:24447364
Montserrat-de la Paz S et al. Long-chain fatty alcohols from evening primrose oil inhibit the inflammatory response in murine peritoneal macrophages. 2014 J Ethnopharmacol pmid:24239848
Wang Y et al. DanQi Pill protects against heart failure through the arachidonic acid metabolism pathway by attenuating different cyclooxygenases and leukotrienes B4. 2014 BMC Complement Altern Med pmid:24555740
Santos-Gallego CG and Badimon JJ The sum of two evils: pneumonia and myocardial infarction: is platelet activation the missing link? 2014 J. Am. Coll. Cardiol. pmid:25444148
Cangemi R et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. 2014 J. Am. Coll. Cardiol. pmid:25444147
Shinohara M et al. Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. 2014 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:25217660
Hong S et al. Maresin-like lipid mediators are produced by leukocytes and platelets and rescue reparative function of diabetes-impaired macrophages. 2014 Chem. Biol. pmid:25200603
Tong B et al. [Atorvastatin inhibits platelet aggregation and activation following carotid balloon injury in cholesterol-fed rabbits]. 2014 Nan Fang Yi Ke Da Xue Xue Bao pmid:25176087
Kaplon-Cieslicka A et al. Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study. 2014 Cardiovasc Diabetol pmid:25123549
Hayashi G et al. Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia. 2014 Hum. Mol. Genet. pmid:25104852
Floyd CN et al. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. 2014 Br J Clin Pharmacol pmid:25099258
Zhu SH et al. Protective effect of indomethacin in renal ischemia-reperfusion injury in mice. 2014 J Zhejiang Univ Sci B pmid:25091992
Basili S et al. Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes. 2014 Circ Cardiovasc Interv pmid:25074252
Lattanzio S et al. Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin. 2014 J Am Heart Assoc pmid:25037197
Santilli F et al. Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. 2014 J Am Heart Assoc pmid:25037196
Patrignani P et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. 2014 J. Thromb. Haemost. pmid:24942808
Mayer AM et al. Vibrio vulnificus MO6-24/O lipopolysaccharide stimulates superoxide anion, thromboxane Bâ‚‚, matrix metalloproteinase-9, cytokine and chemokine release by rat brain microglia in vitro. 2014 Mar Drugs pmid:24675728
van den Elsen LW et al. Dietary fish oil improves endothelial function and lowers blood pressure via suppression of sphingolipid-mediated contractions in spontaneously hypertensive rats. 2014 J. Hypertens. pmid:24569415